Evidence map›Paper›PMID 36284648›Full record

ArticleOncology letters2022

Anti-tumor effects of perampanel in malignant glioma cells.

Juri Tatsuoka, Emiko Sano, Yuya Hanashima, Chihiro Yagi, Shun Yamamuro, Koichiro Sumi, Hiroyuki Hara, Kazuhide Takada, Kazunori Kanemaru, Shihoko Komine-Aizawa and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Intrinsic and Microenvironmental Drivers of Glioblastoma Invasion.International journal of molecular sciences · 2024
    Review
  15. Article
  16. The evaluation of six genes combined value in glioma diagnosis and prognosis.Journal of cancer research and clinical oncology · 2023
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Juri TatsuokaDepartment of Neurological Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Emiko SanoDepartment of Neurological Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Yuya HanashimaDepartment of Neurological Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Chihiro YagiDepartment of Neurological Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Shun YamamuroDepartment of Neurological Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Koichiro SumiDepartment of Neurological Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Hiroyuki HaraDivision of Anatomical Science, Department of Functional Morphology, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Kazuhide TakadaDivision of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Kazunori KanemaruDivision of Biomedical Sciences, Department of Physiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Shihoko Komine-AizawaDivision of Microbiology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Yoichi KatayamaDepartment of Neurological Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Atsuo YoshinoDepartment of Neurological Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Nihon University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma has a poor prognosis even after multimodal treatment, such as surgery, chemotherapy and radiation therapy. Patients with glioblastoma frequently develop epileptic seizures during the clinical course of the disease and often require antiepileptic drugs. Therefore, agents with both antiepileptic and antitumoral effects may be very useful for glioblastoma treatment. Perampanel, an α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor antagonist, is an antiepileptic drug that is widely used for intractable epilepsy. The present study aimed to assess the potential antitumoral effects of perampanel using malignant glioma cell lines. The cell proliferation inhibitory effect was evaluated using six malignant glioma cell lines (A-172, AM-38, T98G, U-138MG, U-251MG and YH-13). A dose-dependent inhibitory effect of perampanel on cell viability was demonstrated; however, the sensitivity of cells to perampanel varied and further antitumoral effects were demonstrated in combination with temozolomide (TMZ) in certain malignant glioma cells. Furthermore, cell cycle distribution and apoptosis induction analyses were performed in T98G and U-251MG cells using a fluorescence activated cell sorter (FACS) and the expression levels of apoptosis-related proteins were evaluated using western blotting. No significant change was demonstrated in the proportions of cells in the G0/G1, S and G2/M phases under 1.0 µM perampanel treatment, whereas induction of apoptosis was demonstrated using FACS at 10 µM perampanel and western blotting at 1.0 µM perampanel in both glioma cell lines. Overexpression of SERPINE1 may be related to poor prognosis in patients with gliomas. The combination of 1.0 µM perampanel and 5.0 µM tiplaxtinin, a SERPINE1 inhibitor, demonstrated further reduced cell viability in perampanel-resistant U-138MG cells, which have high expression levels of SERPINE1. These results indicated that the antitumor effect of perampanel may not be expected for malignant gliomas with higher expression levels of SERPINE1. The findings of the present study suggested that the antiepileptic drug perampanel may also have an antitumor effect through the induction of apoptosis, which is increased when combined with TMZ in certain malignant glioma cells. These findings also suggested that SERPINE1 expression may be involved in perampanel susceptibility. These results may lead to new therapeutic strategies for malignant glioma.

Indexed as

antiepileptic drugglioblastomaperampaneltemozolomideα-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

Identifiers

PMID36284648
PMCPMC9580249
OpenAlexW4303418779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.